EE2012: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours (ESFT).

Trial Overview and Summary

This trial is for the Ewing’s sarcoma family of tumours. The aim is to compare two chemotherapy regimens to see which is more effective.  The two treatment regimens are the VIDE strategy (vincristine, ifosfamide, doxorubicin and etoposide (VIDE) chemotherapy followed by vincristine, actinomycin D and ifosfamide/cyclophosphamide (VAI/VAC) or busulfan and melphalan (VAI/BuMel)), and the VDC/IE strategy (alternating cycles of vincristine, cyclophosphamide, doxorubicin (VDC) and ifosfamide, etoposide (IE) chemotherapy and followed by cycles of ifosfamide, etoposide (IE) and vincristine, cyclophosphamide (VC) or busulfan and melphalan (VAI/BuMel)).  The second aim of the trial is to see if giving a drug called zoledronic acid with this chemotherapy can improve treatment. 

Chief Investigator: Professor Bernadette Brenan
Sponsor: University of Birmingham
Funders: Cancer Research UK (CRUK) and the European Union’s Seventh Framework Programme
Disease Site: Ewing's Sarcoma
Trial Type: Clinical Trial of an Investigational Medical Product
Status: Closed to recruitment
UKCRN Study ID: (if applicable) 13804
Open to new sites? No
Recruitment start date: December 2013
Recruitment end date May 2019
CRCTU Trial Management Team: Children's Cancer Trials Team
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More information